Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
[HTML][HTML] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast …
HJ Burstein, G Curigliano, B Thürlimann, WP Weber… - Annals of oncology, 2021 - Elsevier
The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
virtually, owing to the global COVID-19 pandemic. More than 3300 participants took part in …
Triple negative breast cancer: Pitfalls and progress
P Zagami, LA Carey - NPJ breast cancer, 2022 - nature.com
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
An overview of PARP inhibitors for the treatment of breast cancer
Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …
Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO …
HJ Burstein, MR Somerfield, DL Barton… - Journal of clinical …, 2021 - ascopubs.org
PURPOSE To update recommendations of the ASCO systemic therapy for hormone receptor
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
(HR)-positive metastatic breast cancer (MBC) guideline. METHODS An Expert Panel …
Genomics to select treatment for patients with metastatic breast cancer
Cancer progression is driven in part by genomic alterations. The genomic characterization of
cancers has shown interpatient heterogeneity regarding driver alterations, leading to the …
cancers has shown interpatient heterogeneity regarding driver alterations, leading to the …
Advances in systemic therapies for triple negative breast cancer
Triple negative breast cancer (TNBC) continues to be the subtype of breast cancer with the
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
highest rates of recurrence and mortality. The lack of expression of targetable proteins such …
Triple negative breast cancer: updates on classification and treatment in 2021
Simple Summary Triple negative breast cancer (TNBC) represents 15 to 20% of all breast
cancers in the United States. The main treatment option remains chemotherapy, despite …
cancers in the United States. The main treatment option remains chemotherapy, despite …
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2 …
KA Reiss, R Mick, MH O'Hara, U Teitelbaum… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline …
as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline …
Heterogeneity of triple negative breast cancer: Current advances in subty** and treatment implications
As the field of translational 'omics has progressed, refined classifiers at both genomic and
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …
proteomic levels have emerged to decipher the heterogeneity of breast cancer in a clinically …